2022 - Research.com Best Female Scientist Award
Mary Sano spends much of her time researching Alzheimer's disease, Dementia, Internal medicine, Psychiatry and Disease. Her study in Alzheimer's disease is interdisciplinary in nature, drawing from both Relative risk, Central nervous system disease, Degenerative disease and Pediatrics. Her studies in Dementia integrate themes in fields like Physical therapy, Neuropsychological test, Cognition and Neurology.
Her research integrates issues of Placebo and Surgery in her study of Internal medicine. Her work in Psychiatry addresses subjects such as Donepezil, which are connected to disciplines such as Hazard ratio, Confidence interval and Vitamin E. Her biological study spans a wide range of topics, including PICALM, Psychosis and Computational biology, Systems biology.
Mary Sano mostly deals with Dementia, Disease, Cognition, Gerontology and Alzheimer's disease. Her research integrates issues of Psychiatry, Physical therapy, Cohort and Risk factor in her study of Dementia. In her research on the topic of Disease, Clinical Dementia Rating is strongly related with Clinical trial.
Her biological study spans a wide range of topics, including Type 2 diabetes, Clinical psychology and Cognitive decline. Her Alzheimer's disease research is within the category of Internal medicine. Her Internal medicine research focuses on subjects like Placebo, which are linked to Randomized controlled trial.
Mary Sano focuses on Dementia, Cognition, Cognitive decline, Disease and Gerontology. The study incorporates disciplines such as Prospective cohort study, Randomized controlled trial and Cohort in addition to Dementia. Her Cognition research is multidisciplinary, incorporating elements of Anesthesia and Clinical psychology.
Her Cognitive decline study also includes fields such as
Mary Sano mainly focuses on Dementia, Cognitive decline, Cognition, Internal medicine and Prospective cohort study. Her Dementia study is concerned with the larger field of Disease. Her Cognitive decline research focuses on Depression and how it relates to Alzheimer's disease.
Mary Sano interconnects Psychological intervention, Anesthesia, Informed consent and Diabetes risk in the investigation of issues within Cognition. Her research in the fields of Cohort overlaps with other disciplines such as Induced pluripotent stem cell. As part of one scientific family, Mary Sano deals mainly with the area of Prospective cohort study, narrowing it down to issues related to the Incidence, and often Activities of daily living, Pediatrics, Risk factor and Re experiencing.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Mary Sano;Christopher Ernesto;Ronald G. Thomas;Melville R. Klauber.
The New England Journal of Medicine (1997)
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Ronald C. Petersen;Ronald G. Thomas;Michael Grundman;David Bennett.
The New England Journal of Medicine (2005)
Common variants at MS4A4/MS4A6E , CD2AP , CD33 and EPHA1 are associated with late-onset Alzheimer's disease
Adam C. Naj;Gyungah Jun;Gary W. Beecham;Li-San Wang.
Nature Genetics (2011)
Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial
Paul S. Aisen;Kimberly A. Schafer;Michael Grundman;Eric Pfeiffer.
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease.
Douglas Galasko;David Bennett;Mary Sano;Chris Ernesto.
Alzheimer Disease & Associated Disorders (1997)
Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities.
T K Tatemichi;D W Desmond;Y Stern;M Paik.
Journal of Neurology, Neurosurgery, and Psychiatry (1994)
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
Michael Grundman;Ronald C. Petersen;Steven H. Ferris;Ronald G. Thomas.
JAMA Neurology (2004)
Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community.
Devangere P. Devanand;Mary Sano;Mingxin Tang;Stuart Taylor.
Archives of General Psychiatry (1996)
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
Rachelle S Doody;Svetlana I Gavrilova;Mary Sano;Ronald G Thomas.
The Lancet (2008)
Dementia after stroke Baseline frequency, risks, and clinical features in a hospitalized cohort
T. K. Tatemichi;D. W. Desmond;R. Mayeux;M. Paik.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: